Search results for: 'api frost radar'

This study provides a comprehensive analysis of the contract research and manufacturing services (CRAMS) segment in India by focusing on drug discovery to pre-clinical toxicology, Active Pharmaceutical Ingredient (API), Formulations and Injectables. The study is based on detailed primary research, and includes an evaluation of the market size as we...

05 Apr 2023  |  Asia Pacific  |  Market Outlook

Asia-Pacific Pharmaceutical Industry Outlook, 2023

Disruptive Technology Adoption and Outsourcing Growth is Advancing Innovation in the Pharmaceutical Industry

Infographics

×

Asia-Pacific’s pharmaceutical market is forecast to record 4.2% growth from 2022 to 2027, with China and Japan dominating the market in terms of value. Generics dominate the regional markets based on volume, directly impacting innovator molecule uptake. Nevertheless, Asia-Pacific is establishing itself as a global innovation hub, with China, Japan,...

Increased competition between healthcare providers which has lead to increased development of competitive features, such as premium care facilities, aesthetic and wellness medicine facilities, improved patient customer service, and so on. This has also stimulated the increased application of technology in both medical devices and information and c...

Frost & Sullivan has recently completed a comprehensive analysis on the current and future strategic imperatives of game-changing Asia-Pacific (APAC) pharmaceutical companies. The analysis primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing...

10 Jan 2018  |  Asia Pacific  |  Market Research

APAC Biosimilar Market, Forecast 2025

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

Infographics

×

Key Issues Addressed Key Benefits

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, o...